A new case report titled "Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report" has been published in Oncotarget.
Jan 24, 2024
0
0
For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), osimertinib with chemotherapy leads to significantly longer progression-free survival (PFS) compared with osimertinib alone, according to a study ...
Nov 16, 2023
0
1
Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to osimertinib alone, according to research presented at the International Association ...
Sep 11, 2023
0
7
When lung cancers driven by mutations in the EGFR gene become resistant to osimertinib or other targeted therapies, epigenetic changes, rather than genetic changes, are often to blame.
Aug 3, 2023
0
6
New data from a Yale Cancer Center-led clinical trial shows improved rates of survival and reduced risk of recurrence in patients taking osimertinib, a targeted therapy for non-small cell lung cancer (NSCLC). NSCLC is the ...
Jan 31, 2023
0
21
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumor resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC). In an early benefit assessment, the German Institute ...
Oct 1, 2021
0
5
Two presentations from the ADAURA clinical trial advanced previous research that demonstrated improved disease-fee survival (DFS) outcomes for patients with surgically resected non-small cell lung cancer (NSCLC) receiving ...
Jan 29, 2021
0
4
The effectiveness of cancer treatment is often hampered by cancer cells being heterogeneous. This is the case for EGFR-mutated lung cancer: drugs based on biomolecules of a type known as tyrosine kinase inhibitor (TKI) have ...
Oct 5, 2020
0
6
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance ...
Sep 14, 2020
0
7
In two decisions published today, the National Institute for Health and Care Excellence (NICE) has approved the drug osimertinib (Tagrisso) to treat some adults in England with advanced lung cancer whose cancer tests positive ...
Sep 14, 2020
0
6
